Eli Lilly and Company (NYSE:LLY) Stock Holdings Lifted by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 415 shares of the company’s stock after buying an additional 15 shares during the quarter. Levin Capital Strategies L.P.’s holdings in Eli Lilly and Company were worth $242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC raised its stake in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company during the 4th quarter valued at $363,000. Terril Brothers Inc. boosted its holdings in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares during the period. Hartline Investment Corp grew its position in Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after purchasing an additional 248 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Eli Lilly and Company by 5.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock worth $206,683,000 after purchasing an additional 17,461 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LLY. Truist Financial boosted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday. Morgan Stanley increased their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Citigroup boosted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Stock Down 2.8 %

Shares of Eli Lilly and Company stock traded down $20.94 on Friday, hitting $734.97. The company had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. The stock has a 50-day moving average of $761.75 and a 200-day moving average of $670.56. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The firm has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.57 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.62 EPS. Research analysts predict that Eli Lilly and Company will post 13.49 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.